文献速递流行病学与生物统计真实世界研究与卫生经济

利用ClinicalTrials.gov评估核心结局指标集采纳率的方法学:基于类风湿关节炎随机对照试验综述的发现

A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: findings from a review of randomised controlled trials of rheumatoid arthritis.
PubMed 文献 · BMJ · 2017-05-17

该研究基于ClinicalTrials.gov 2002至2016年间注册的273项类风湿关节炎药物干预随机试验,提出一种从注册信息计算核心结局指标集采纳率的新方法。结果显示,在注册库中标记为已完成或终止且可在文献或注册库找到结果的试验中,81%(116/143)报告了完整核心结局指标集;仅用注册库信息估算的采纳率为77%(145/189)。作者认为注册库信息可合理估算采纳率,且比查阅已发表试验报告更高效、更及时。

要点

  • 基于注册库信息估算类风湿关节炎核心结局指标集采纳率为77%(145/189)。
  • 在可获取结果的已完成或终止试验中,81%(116/143)报告了完整核心结局指标集。
  • 利用注册库结局信息估算核心结局指标集采纳率更高效、更及时。

核心结论

  • 类风湿关节炎核心结局指标集在临床试验中的采纳率随时间持续增加。
  • 利用试验注册库中已完成或终止研究的结局信息可合理估算核心结局指标集的采纳率,且比查阅已发表试验报告更高效、更及时。
  • 所提出的方法或可为已发表的300个核心结局指标集提供高效的实时采纳率评估途径。

研究设计与样本

  • 研究设计为随机试验综述。
  • 数据来源为ClinicalTrials.gov。
  • 研究对象为2002至2016年间注册于ClinicalTrials.gov的273项类风湿关节炎药物干预随机试验。
  • 通过试验注册库信息或使用Google及Web of Science引文数据库的网络检索,识别已完成研究的全文发表文献。

主要发现

  • 在注册库中标记为已完成或终止且可在已发表文献或注册库中找到结果的试验中,81%(116/143)报告了完整的类风湿关节炎核心结局指标集。
  • 对于注册库中标记为已完成或终止的试验,仅使用注册库中可得信息估算的采纳率为77%(145/189)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective To assess the uptake of the rheumatoid arthritis core outcome set using a new assessment method of calculating uptake from data in clinical trial registry entries.Design Review of randomised trials.Setting ClinicalTrials.gov.Subjects 273 randomised trials of drug interventions for the treatment of rheumatoid arthritis and registered in ClinicalTrials.gov between 2002 and 2016. Full publications were identified for completed studies from information in the trial registry or from an internet search using Google and the citation database Web of Science.Main outcome measure The percentage of trials reporting or planning to measure the rheumatoid arthritis core outcome set calculated from the information presented in the trial registry and compared with the percentage reporting the rheumatoid arthritis core outcome set in the resulting trial publications.Results The full rheumatoid arthritis core outcome set was reported in 81% (116/143) of trials identified on the registry as completed (or terminated) for which results were found in either the published literature or the registry. For trials identified on the registry as completed (or terminated), using information only available in the registry gives an estimate for uptake of 77% (145/189).Conclusions The uptake of the rheumatoid arthritis core outcome set in clinical trials has continued to increase over time. Using the information on outcomes listed for completed or terminated studies in a trial registry provides a reasonable estimate of the uptake of a core outcome set and is a more efficient and up-to-date approach than examining the outcomes in published trial reports. The method proposed may provide an efficient approach for an up-to-date assessment of the uptake of the 300 core outcome sets already published.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Kirkham JJ, Clarke M, Williamson PR, et al. A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: findings from a review of randomised controlled trials of rheumatoid arthritis. BMJ. 2017. PMID: 28515234. doi:10.1136/bmj.j2262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。